Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
30High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05677373CT.gov Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | — | Withdrawn | — | — | — |
NCT03297424CT.gov A Study of PLX2853 in Advanced Malignancies. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| plx2853 (this asset) | Alliance for Clinical Trials in Oncology | P1/2 | CC · 45 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for plx2853
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic Syndrome | — | P1 | C · 38 |
| Acute Myeloid Leukemia | — | P1 | C · 38 |
| Cancer | — | P1 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. plx2853 in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/plx2853-uveal-melanoma-106320
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →